Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tarsa Therapeutics

Request full access

Develops an oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis

Philadelphia, United StatesFounded 2009Biotech & Life Sciences

About Tarsa Therapeutics

Tarsa Therapeutics is a biopharmaceutical company specializing in the development of novel treatments for postmenopausal osteoporosis. The company has developed an innovative oral formulation of calcitonin, a natural hormone with a long history of safety and efficacy in treating osteoporosis. This product, known as TBRIA, is designed for women more than five years post-menopause who cannot use alternative treatments. Tarsa Therapeutics operates in the healthcare and pharmaceutical market, targeting a niche segment of postmenopausal women with specific medical needs. The business model revolves around the development, clinical testing, and eventual commercialization of their proprietary oral calcitonin formulation. Revenue is generated through licensing agreements, partnerships, and potential sales of the approved treatment. TBRIA has demonstrated positive safety and efficacy in the global, randomized, double-blind Phase 3 ORACAL trial, showing statistical superiority to both placebo and nasal calcitonin spray in increasing bone mineral density at the lumbar spine after 48 weeks of use. The safety profile of TBRIA did not substantially differ from nasal calcitonin or placebo.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2009
Headquarters
Philadelphia, United States
Employees
3
Open positions
None listed
Dealroom signal
24.7/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotech & Life Sciences, Risk Management, Biotechnology, Oncology, DNA, Genetics and genomics, Orthopedic, Genome Engineering, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
DEBTDebt Jul 2016 $1.2M — Square 1 Bank · Oxford Finance —
DEBTDebt Feb 2016 $2M — Square 1 Bank · Oxford Finance —
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Tarsa Therapeutics website traffic

Latest recorded traffic for Tarsa Therapeutics is 260 monthly website visits, up 550% over the last three months. Tarsa Therapeutics's team grew 0% over the past year.

Latest monthly visits260 3-month web change+550% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Tarsa Therapeutics in the Philadelphia ecosystem

Live from Dealroom

The Tarsa Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Series B and later2 investors entered at this stage

  • Square 1 Bank
  • Oxford Finance
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tarsa Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tarsa Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.